Evaluating the efficacy and safety of Anlotinib in conjunction with stereotactic radiosurgery for small cell lung cancer patients with brain metastases
Year: 2024
Type: article
Abstract: Background: Small cell lung cancer (SCLC) is characterized by its aggressive nature and high propensity for brain metastases. This study investigates the clinical efficacy and safety profile of Anlotinib in combination with Stereotactic Radiotherapy (SRT) for treating brain metastases in patients with small cell lung cancer (SCLC). Methods: This research included 98 SCLC brain metastasis patients treated at Chengde Central Hospital from October 2020 to January 2024. The patients were categorized into a combined treatment group (CTG) (n = 45) and a Simple SRT group (SSG)(n = 53). The CTG (58 lesions) received Anlotinib with brain SRS, while the SSG (67 lesions) underwent only brain SRS. We compared the rates of intracranial hypertension relief, intracranial lesion treatment efficacy, radiation-induced brain necrosis, intracranial progression-free survival, and overall survival between the groups. Additionally, Anlotinib usage and adverse reactions in the CTG were documented. Results: = 0.3506). The duration of Anlotinib treatment in the CTG was 6 (6, 18) weeks. Adverse reactions included Grade I hypertension in three patients and Grade I hand-foot skin reactions in two patients, with a drug-related adverse reaction rate of 11.1% (5/45). Conclusion: Anlotinib combined with SRT significantly alleviates brain edema, reduces the incidence of radiation-induced brain necrosis, enhances intracranial progression-free survival, and demonstrates a low adverse reaction rate.
Institution: Affiliated Hospital of Chengde Medical College
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4401890486